Company announcement - No. 44 / 2017
Zealand Pharma to present at Morgan Stanley Global Healthcare Conference in New York on September 12, 2017
Copenhagen, September 5, 2017 -
Britt Meelby Jensen, President and Chief Executive Officer (CEO) of Zealand Pharma, will present at the Morgan Stanley Global Healthcare Conference in New York, at the Grand Hyatt hotel on Wednesday, September 12, 2017 at 1 pm (EST). Britt Meelby Jensen will open with brief remarks on Zealand Pharma's progress and strategic direction, transitioning into a "fireside chat" question and answer session.
For further information, please contact:
Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: firstname.lastname@example.org
bout Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.
Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin® in the U.S. and as Lyxumia® in the rest of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus®) and is marketed as Soliqua® 100/33 in the U.S. and has been approved as Suliqua® in Europe and launched in the Netherlands.
Zealand's clinical pipeline includes: dasiglucagon (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (Phase 3); glepaglutide (ZP1848) for short bowel syndrome (Phase 2 completed); dasiglucagon (ZP4207, multiple-dose version) intended for use in a dual-hormone artificial pancreas system to reduce the risk of hypoglycemia and better diabetes management (Phase 2) as well as for the treatment of congenital hyperinsulinism, and other earlier-stage clinical and preclinical peptide therapeutics.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on Linked-in or Twitter @ZealandPharma.